Revolution Medicines: It's Full Steam Ahead, But I Wouldn't Buy At These Levels [Seeking Alpha]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Seeking Alpha
Summary Revolution Medicines' promising KRAS inhibitors show potential in treating difficult cancers, but the $7 billion valuation is high for a pre-commercial entity. RMC-6236 targets multiple KRAS mutations, showing favorable progression-free survival in pancreatic cancer trials, with a phase 3 trial planned for late 2024. Despite a strong cash position, RVMD's high burn rate and reliance on a single novel drug pose significant financial risks. While RVMD's clinical program is impressive, the stock's volatility and long timeline to approval suggest waiting for a more favorable entry point. Alistair Berg Topline Summary and Update Revolution Medicines ( NASDAQ: RVMD ) has been on the forefront of novel targeted therapies since its inception, although the focus has changed substantially. These days, their most promising pipeline candidates are RAS inhibitors that are hoped to dramatically widen the pool of patients with cancer who can benefit from this brand of targeted
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at HC Wainwright from $62.00 to $64.00. They now have a "buy" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Needham & Company LLC from $61.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $54.00 to $63.00. They now have an "overweight" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Piper Sandler from $57.00 to $70.00. They now have an "overweight" rating on the stock.MarketBeat
- Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 11/6/24 - Miss
RVMD
Sec Filings
- 11/8/24 - Form 4
- 11/8/24 - Form SC
- 11/6/24 - Form 144
- RVMD's page on the SEC website